Tenax shares nosedive as heart failure drug fails in Phase 3
Patients treated with Tenax Therapeutics’ heart failure drug TNX-103 did not show significantly better functional performance—though Leerink analysts found biomarker improvements and subgroup analyses in elderly and more severe patients “very encouraging.”
Tenax shares nosedive as heart failure drug fails in Phase 3 Read More »
